Newsfilter article unlocker

Enter Newsfilter article ID in the field below.
Example: https://newsfilter.io/articles/39be1bef03e66cdc886c08a2a6319c47

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report first quarter 2026 financial results on Thursday, May 14, 2026. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Title: Cibus, Inc. First Quarter 2026 Results Conference Call

Event Date: Thursday, May 14, 2026        

Time: 4:30 p.m. ET        

Participant Numbers: +1-800-274-8461 (U.S.), +1-203-518-9814 (International)

The conference ID "CIBUS" or 24287 will be required for entry

Event Link: https://investor.cibus.com/events

For interested individuals unable to join the conference call, a dial-in replay of the call will be available through Thursday, May 28, 2026, and can be accessed by dialing +1-844-512-2921 (U.S.), +1-412-317-6671 (International) and entering replay passcode: 11161515.

A live audio webcast of the call, along with accompanying slides, will be available under "News & Events" in the Investor section of the Company's website, investor.cibus.com. An archived webcast will be available on the Company's website for 90 days after the event.

About Cibus

Cibus is a leader in developing traits (characteristics) that address critical productivity, yield and sustainability challenges. Cibus' proprietary high-throughput gene editing technologies drive its long-term focus on productivity traits for farmers for the major global row crops. Cibus is not a seed company. It is a technology company that uses its gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and to license them to customers in exchange for royalties.

Cibus Contacts:

Investor Relations

Jeff Sonnek – ICR

jeff.sonnek@icrinc.com

Media Relations

Colin Sanford

colin@bioscribe.com

203-918-4347